ID 110657
Author
Ozaki, Shuji First Department of Internal Medicine, The University of Tokushima School of Medicine
Kosaka, Masaaki First Department of Internal Medicine, The University of Tokushima School of Medicine
Keywords
multiple myeloma
biology
treatment
hematopoietic stem cell transplantation
immunotherapy
Content Type
Journal Article
Description
Recently, considerable progress has been made in understanding of the biology and treatment of multiple myeloma. Molecular genetic abnormalities such as bcl-2,c-myc, ras, p53, and Rb genes have been identified in this disease and are related to a poor prognosis. Cytokine studies have revealed that interleukin-6 is a potent growth factor for myeloma cells and is also responsible for the progressive bone resorption together with interleukin-1 βand tumor necrosis factor. Myeloablative chemotherapy followed by allogeneic or autologous hematopoietic stem cell transplantation has increased the incidence of complete remission. However, relapses are still observed because of drug resistance of tumor cells. Immunotherapeutic approaches targeting to cell surface antigens andinterleukin-6 signals are being developed to further eliminate myeloma cells. Translating new biological advances into treatment protocols is essential to improve the prognosis of multiple myeloma.
Journal Title
The journal of medical investigation : JMI
ISSN
13431420
NCID
AA11166929
Volume
44
Issue
3-4
Start Page
127
End Page
136
Sort Key
127
Published Date
1998
EDB ID
FullText File
language
eng
TextVersion
Publisher